Benefits
Diabetic Peripheral Neuropathy
ALPHA-LIPOIC ACID has the strongest evidence base for any natural compound for diabetic peripheral neuropathy. SYDNEY 2 trial (Ziegler 2006), ALADIN III, and others established efficacy. R-ALA is the active enantiomer; racemic ALA contains 50% S-form which has minimal activity. Most clinical trials used racemic but R-ALA is the active component.
Antioxidant Activity (Both Water and Lipid Soluble)
ALA is unique among antioxidants in being BOTH water-soluble AND lipid-soluble — accesses both cellular environments. Recycles other antioxidants (vitamin C, vitamin E, glutathione, CoQ10). 'Universal antioxidant' positioning.
Insulin Sensitivity / Blood Sugar
Improves insulin sensitivity in T2DM and metabolic syndrome. Ansar 2011 and others showed modest glycemic effects. Effect modest; not substitute for evidence-based diabetes medications.
Mitochondrial Function
Endogenous mitochondrial cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes. Supports cellular energy production.
Heavy Metal Chelation
ALA chelates heavy metals (mercury, arsenic, cadmium) — used in chelation protocols by some practitioners. Modest evidence; not first-line for clinical heavy metal toxicity.
Mechanism of action
Endogenous Mitochondrial Cofactor
R-ALA is the naturally-occurring enantiomer in mitochondria — bound to specific lysine residues on enzymes (lipoyllysine). Cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, glycine cleavage system.
R-ALA vs S-ALA Activity
R-form is biologically active; S-form has minimal direct biological activity. Racemic ALA (50/50 mix) effectively delivers half the active dose at same mg quantity. PURE R-ALA is therefore approximately twice as potent per mg.
Glutathione Recycling
ALA reduces oxidized glutathione (GSSG) back to active GSH — supporting endogenous antioxidant capacity beyond just direct ALA antioxidant effects.
AMPK Activation
Activates AMP-activated protein kinase (AMPK) — improving glucose uptake, insulin sensitivity, fat oxidation. Same target as metformin and exercise.
Clinical trials
Multicenter RCT of ALA (600, 1,200, or 1,800 mg/day racemic) vs placebo in 181 diabetic peripheral neuropathy patients for 5 weeks.
181 diabetic neuropathy patients.
All ALA doses significantly improved Total Symptom Score (TSS) vs placebo. 600 mg/day optimal dose-response. Established ALA as evidence-based treatment for diabetic neuropathy. Ziegler 2011 meta-analysis confirmed.
Multiple trials of ALA for glycemic control in T2DM and metabolic syndrome.
T2DM and metabolic syndrome patients.
Modest improvements in fasting glucose, HbA1c, insulin sensitivity. Effect smaller than metformin or other established diabetes therapies. Reasonable adjunct.
About this ingredient
R-LIPOIC ACID (R-ALA, R-LA, or (R)-(+)-alpha-lipoic acid) is the BIOLOGICALLY ACTIVE ENANTIOMER of alpha-lipoic acid — the naturally-occurring form in mitochondria.
CRITICAL DISTINCTION FROM RACEMIC ALA: (1) RACEMIC ALA — standard supplement form; 50/50 mixture of R and S enantiomers; cheap; clinical trials predominantly used this form; the S-form has minimal biological activity (excreted, modestly retoxified by R-form, possibly inhibitory at high concentrations); (2) PURE R-ALA — biologically active form; ~2× more potent per mg vs racemic; more expensive; requires stabilization. STABILITY ISSUE: pure R-ALA is unstable at room temperature — polymerizes and loses activity. STABILIZED FORMS: (a) NA-R-ALA (sodium R-lipoic acid) — improved stability and bioavailability; (b) BIOENHANCED® R-LIPOIC ACID (Geronova Research) — patented stabilization technology; (c) MICROENCAPSULATED R-ALA — alternative stabilization. For DOSING: pure R-ALA at 100-300 mg/day approximately equivalent to racemic ALA at 200-600 mg/day. BIOAVAILABILITY: R-ALA bioavailability ~30%; better when taken WITHOUT food (food reduces absorption ~30%); take 30 min before meals or 2+ hours after.
EVIDENCE-BASED USES: (1) DIABETIC PERIPHERAL NEUROPATHY — strongest evidence; established by SYDNEY 2 and other major trials; (2) Insulin sensitivity / glycemic adjunct; (3) General antioxidant support; (4) Mitochondrial function support; (5) Heavy metal chelation (modest); (6) Anti-aging stack component (BIOLOGICAL ACTIVITY supports longevity claims).
CRITICAL CAUTIONS: (1) HYPOGLYCEMIA — significant risk especially with insulin/sulfonylureas; monitor blood glucose; consult prescriber if on diabetes medications; (2) INSULIN AUTOIMMUNE SYNDROME (HIRATA'S DISEASE) — rare but documented; ALA-induced anti-insulin antibodies cause severe hypoglycemia; HLA-DRB1*04:06 predisposes (more common in Japanese populations); reversible with discontinuation; check for unexplained severe hypoglycemia in users; (3) PRE-SURGERY — discontinue 1-2 weeks before surgery to avoid intraoperative hypoglycemia; (4) THYROID MEDICATIONS — theoretical reduced absorption; separate by 4 hours; (5) PREGNANCY/LACTATION — limited safety data at supplemental doses; AVOID supplementation; food sources safe; (6) DOSE — 100-300 mg/day R-ALA (equivalent to 200-600 mg/day racemic); 600 mg/day racemic for diabetic neuropathy; up to 1,200 mg studied; (7) TIMING — empty stomach (food reduces absorption); divided doses (e.g., 100 mg twice daily) better than single large dose; (8) RACEMIC VS R-ALA — for cost-conscious users, racemic ALA at higher dose is reasonable substitute for R-ALA; clinical trials largely used racemic so evidence base is for that form; (9) DIABETIC NEUROPATHY — ALA is one of few evidence-based supplements for this indication; gold standard pharmacotherapy includes pregabalin, gabapentin, duloxetine, but ALA is reasonable adjunct or first-line for those preferring natural approach; address glycemic control as foundational; (10) DOSE LIMITS — chronic high doses may cause B-vitamin depletion (theoretical); consider B-complex co-supplementation; (11) The R-ALA premium is justified primarily for those seeking maximum potency in lower volume; for routine use, racemic ALA at appropriate doses (600 mg/day) achieves clinical benefits at lower cost.